Literature DB >> 23456263

Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.

Tomotaka Suzuki, Shigeru Kusumoto, Tatsuya Yoshida, Fumiko Mori, Asahi Ito, Masaki Ri, Takashi Ishida, Hirokazu Komatsu, Akio Niimi, Shinsuke Iida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23456263     DOI： 10.1007/s12185-013-1301-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  6 in total

1.  Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.

Authors:  Tereza Coman; Emmanuel Bachy; Mauricette Michallet; Gérard Socié; Madalina Uzunov; Jean Henri Bourhis; Simona Lapusan; Alain Brebion; Stéphane Vigouroux; Sébastien Maury; Sylvie François; Anne Huynh; Bruno Lioure; Ibrahim Yakoub-Agha; Olivier Hermine; Noël Milpied; Mohamad Mohty; Marie Thérèse Rubio
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

2.  Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Authors:  Evelien Kneppers; Bronno van der Holt; Marie-Jose Kersten; Sonja Zweegman; Ellen Meijer; Gerwin Huls; Jan J Cornelissen; Jeroen J Janssen; Cynthia Huisman; Petra B Cornelisse; Cheryl P Bruijnen; Maarten Emmelot; Pieter Sonneveld; Henk M Lokhorst; Tuna Mutis; Monique C Minnema
Journal:  Blood       Date:  2011-06-20       Impact factor: 22.113

3.  International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

Authors:  Henk Lokhorst; Hermann Einsele; David Vesole; Benedetto Bruno; Jesus San Miguel; Jose A Pérez-Simon; Nicolaus Kröger; Philippe Moreau; Gosta Gahrton; Cristina Gasparetto; Sergio Giralt; William Bensinger
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 4.  Lenalidomide: a novel anticancer drug with multiple modalities.

Authors:  Christine Galustian; Angus Dalgleish
Journal:  Expert Opin Pharmacother       Date:  2009-01       Impact factor: 3.889

5.  Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Authors:  N Kröger; T Zabelina; E Klyuchnikov; M Kropff; K-H Pflüger; A Burchert; T Stübig; C Wolschke; F Ayuk; Y Hildebrandt; U Bacher; A Badbaran; G Schilling; T Hansen; D Atanackovic; A R Zander
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

6.  Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Authors:  M Lioznov; J El-Cheikh; F Hoffmann; Y Hildebrandt; F Ayuk; C Wolschke; D Atanackovic; G Schilling; A Badbaran; U Bacher; B Fehse; A R Zander; D Blaise; M Mohty; N Kröger
Journal:  Bone Marrow Transplant       Date:  2009-07-06       Impact factor: 5.483
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.